STALICLA Appoints Stéphane Baudouin as Chief of Science
18.10.2019 01:01:00 EEST | Business Wire | Press release
STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA).
STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/
STALICLA's Chief of Science - Stéphane Baudouin (Photo: STALICLA)
Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior Lecturer and Team Leader at Cardiff University working on research projects funded by the Wellcome Trust and the Welsh Government. Stéphane has extensive track record of collaboration within the ASD basic and translational research community notably on ASD pharmacology related research. His work has been published in numerous high impact peer-reviewed scientific journals.
Commenting on the appointment, Stéphane said:
“My decision to join STALICLA was motivated by the need to bring tangible advancement to how ASD is treated and real change to the lives of people living with these disorders. STALICLA’s approach to bringing personalized treatments to the neurodevelopmental disorder field is unique and potentially transformational. I’m excited to be part of this team and apply my experience to achieve this goal.”
Stéphane was an active member of STALICLA’s Scientific Advisory Board for over two years prior to taking up the new position. As Chief of Science, he will have overall responsibility to shape STALICLA’s pre-clinical development strategy. He will also be in charge of identifying and managing novel partnerships to support STALICLA’s regulatory needs.
“Stéphane’s extensive experience in the cellular and molecular underpinnings of Autism Spectrum Disorder will be invaluable to our research which focuses on the translation of biological and clinical data to develop precision therapeutics for patients with ASD. He is an incredibly talented addition to our team of experts and I wish him every success in his new role as Chief of Science.”
said Lynn Durham, STALICLA’s CEO & Founder
About STALICLA
STALICLA is a near clinical Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDD). First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need.
In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive player, using its DEPIv3 innovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments.
It is the first time that such technologies have been utilized within the field of neurodevelopment with the potential to change the direction of the specialty.
In just over 2 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups.
STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned in Q1 2020.
To support its platform and pipeline development, STALICLA has developed a network of top tier research and clinical partners in the US.
This has enabled STALICLA to gather one of the largest Autism patients Electronic Health Records database to date.
STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.
For more information : http://www.stalicla.com/news/stalicla-pre-ind-meeting-with-fda-on-stp1/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005803/en/
Contact information
Sarbjit Kunar
communication@stalicla.com
+41 22 545 12 42
www.stalicla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cordica Medical Launches PTFE Etched Liners for Interventional Catheter Designs16.11.2026 14:00:00 EET | Press release
Cordica Medical (Cordica), a medical device contract development and manufacturing organization (CDMO), today launched its PTFE Etched Liner portfolio: lubricious ID, bond-ready etched OD PTFE liners for interventional catheter designs, from cardiovascular to neurovascular and more. Standard sizes are available now on the Cordica webstore and ship in 48 hours. Custom sizes are built in 2–3 weeks. The launch coincides with the first day of COMPAMED 2026 in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116876181/en/ Pictured: Cordica’s PTFE Etched Liner. Each liner has a low-friction PTFE inner diameter designed to facilitate device and guidewire passage with a chemically etched outer diameter surface that is designed to enhance bonding to the catheter jacket. The liners are designed to be drawn down over a mandrel for a snug fit and a defined ID before braiding, coiling, and jacketing, and the thin wa
2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 14:00:00 EET | Press release
The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “For generations, Bacardi has had a front-row seat to what’s next in drinks. By combining insights from bar teams, leading venues
Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release
Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu
SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release
SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can
Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release
Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
